Zhao Tianyi, Zhang Yu, Liu Liangbo, Deng Xingmei, Guo Jia, Cao Shuzhu, Zhu Dexin, Xu Jian, Nikolaevna Usevich Vera, Maratbek Suleimenov, Wang Zhen, Sun Zhihua, Gu Xinli, Zhang Hui
State International Joint Research Center for Animal Health Breeding, College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Herbivorous Animal Bacterial Disease Innovation Team, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, China.
ACS Omega. 2023 Jul 28;8(31):28797-28812. doi: 10.1021/acsomega.3c03716. eCollection 2023 Aug 8.
Human brucellosis is one of the world's most common zoonoses, caused by infection and characterized by induced inflammation, which in severe cases can lead to abortion and sterility in humans and animals. There is growing evidence that traditional Chinese medicine (TCM) is beneficial as an adjunct to the treatment of brucellosis. However, its specific targets of action and molecular mechanisms remain unclear. In this study, a systematic pharmacological approach was applied to demonstrate pharmacological targets, biological functions, and signaling pathways of TCM as an adjunct to the treatment of brucellosis (TCMTB). The results of network pharmacology were further verified by in vitro experiments. Network analysis revealed that 133 active ingredients and 247 targets were screened in TCMTB. Further data analysis identified 21 core targets and 5 core compounds in TCMTB, including beta-sitosterol, quercetin, kaempferol, luteolin, and paeoniflorin. Gene ontology and the Kyoto Encyclopedia of Gene and Genome analysis showed that TCMTB might actively treat brucellosis by regulating inflammatory response, enhancing immune function, and targeting signaling pathways such as tuberculosis and TNF. Molecular docking results showed that multiple compounds could bind to multiple targets. Further, in vitro experiments confirmed that quercetin, among the active compounds screened, induced the strongest immunomodulatory and pro-inflammatory cytokine production during infection. Further, quercetin induced nitric oxide production, which attenuated the ability of to internalize THP-1 cells as well as intracellular survival. This study reveals the mechanism by which TCMTB aids in the treatment of brucellosis through a synergistic multicomponent, multipathway, and multitarget action. The contribution of quercetin treatment to infection was demonstrated for the first time, which may be related to the quercetin-induced production of nitric oxide and immunomodulatory and inflammatory cytokines. These predictions of the core compounds and targets may be used in the future for the clinical treatment of brucellosis.
人类布鲁氏菌病是世界上最常见的人畜共患病之一,由感染引起,其特征为引发炎症,严重情况下可导致人类和动物流产及不育。越来越多的证据表明,中药作为布鲁氏菌病治疗的辅助手段有益。然而,其具体作用靶点和分子机制仍不清楚。在本研究中,应用系统药理学方法来证明中药辅助治疗布鲁氏菌病(TCMTB)的药理靶点、生物学功能和信号通路。网络药理学结果通过体外实验进一步验证。网络分析显示,在TCMTB中筛选出133种活性成分和247个靶点。进一步的数据分析确定了TCMTB中的21个核心靶点和5种核心化合物,包括β-谷甾醇、槲皮素、山奈酚、木犀草素和芍药苷。基因本体论和京都基因与基因组百科全书分析表明,TCMTB可能通过调节炎症反应、增强免疫功能以及靶向结核病和肿瘤坏死因子等信号通路来积极治疗布鲁氏菌病。分子对接结果表明,多种化合物可与多个靶点结合。此外,体外实验证实,在所筛选的活性化合物中,槲皮素在感染期间诱导最强的免疫调节和促炎细胞因子产生。此外,槲皮素诱导一氧化氮产生,这减弱了其内化THP-1细胞的能力以及细胞内存活能力。本研究揭示了TCMTB通过协同的多成分、多途径和多靶点作用辅助治疗布鲁氏菌病的机制。首次证明了槲皮素治疗对感染的作用,这可能与槲皮素诱导一氧化氮产生以及免疫调节和炎症细胞因子有关。这些核心化合物和靶点的预测未来可能用于布鲁氏菌病的临床治疗。